We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Tool Facilitates Study of Mitochondrial DNA Variation

By LabMedica International staff writers
Posted on 17 Mar 2015
Print article
Image: The Mseek technique uses enzymes to purify mitochondrial DNA by deleting the nuclear DNA, leaving behind the pure mitochondrial DNA to be sequenced (Photo courtesy of the Middle East Molecular Biology Society).
Image: The Mseek technique uses enzymes to purify mitochondrial DNA by deleting the nuclear DNA, leaving behind the pure mitochondrial DNA to be sequenced (Photo courtesy of the Middle East Molecular Biology Society).
A new tool has been developed that enables researchers to study mitochondrial heteroplasmy and which will aid them in achieving better understanding of its impact on health and disease.

Investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) described their "Mseek" technology in a paper published in the February 27, 2015, issue of the journal Nucleic Acids Research.

Heteroplasmy is the presence of a mixture of more than one type of an organellar genome (mitochondrial DNA (mtDNA) or plastid DNA) within a cell or individual. It is a factor for the severity of mitochondrial diseases. Since most eukaryotic cells contain many hundreds of mitochondria with hundreds of copies of mtDNA, it is possible and indeed very frequent for mutations to affect only some mitochondria while others are unaffected. Heteroplasmy can be beneficial rather than detrimental insofar as centenarians show a higher than average degree of heteroplasmy.

Study of mitochondrial heteroplasmy has been complicated by the relatively small amount of mtDNA in each cell (less than 1% of the total DNA) and the intercellular variability of mtDNA content. To counter these problems, the Mt. Sinai investigators developed Mseek, which combines an enzymatic technique that purifies mitochondrial DNA by deleting the nuclear DNA and an advanced deep DNA sequencing procedure for analysis of the pure mitochondrial DNA.

The investigators reported that Mseek yielded high purity (greater than 90%) mtDNA, and that its ability to detect rare variants was limited only by sequencing depth, providing unprecedented sensitivity and specificity. Using Mseek, they confirmed the ubiquity of heteroplasmy by analyzing mtDNA from a diverse set of cell lines and human samples. Applying Mseek to colonies derived from single cells, they found that heteroplasmy was stably maintained in individual daughter cells over multiple cell divisions.

“Researchers have struggled to sequence mtDNA accurately and in a cost effective manner,” said senior author Dr. Ravi Sachidanandam, assistant professor of oncological sciences at the Icahn School of Medicine at Mount Sinai. “The technique we have developed will allow us to identify dysfunction within mitochondria and makes mtDNA a useful biomarker as well as a potential therapeutic target in cancer and many inherited diseases. We hypothesized that heteroplasmy could be stabilized by intercellular exchange of mtDNA. Our results demonstrated the exchange of mtDNA is possible and heteroplasmy can be maintained stably through this mechanism. This technique could provide a novel platform to investigate features of heteroplasmy in normal and diseased state and in the future, the exchange mechanism could be used as a treatment that targets bad mtDNA and exchanges it with good mtDNA.”

Related Links:

Icahn School of Medicine at Mount Sinai


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.